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   Alzheimer’s disease (AD) affects over 5 million individuals in the United States annually. By 
the year 2050, the number of individuals living with AD is projected to triple (Latest 
Alzheimer’s Facts and Figures, 2016).  Although there is no cure for AD, there are many 
prescriptive pharmacologic agents used to help manage the clinical manifestations of the disease. 
Complementary and alternative medicines (CAM) and herbal supplements are also used in the 
treatment of AD, however indications for their use and effectiveness during the progression of 
AD have not been examined. The purpose of this study was to examine the use of herbal 
supplements in managing the clinical manifestations of AD. The secondary purpose was to 
compare a variety of herbal supplements used to treat the clinical manifestations of AD and to 
evaluate the most widely used and most beneficial for clinical practice. A literature review 
examining herbal supplements and their risks, benefits, and uses in AD was conducted from 
multiple online databases. Peer reviewed articles published in the English language from 1998-
2016 that focused on herbal supplements used to control the clinical manifestations of mild to 
severe AD were included for synthesis. Results from 14 studies that used herbal supplements as a 
treatment for the clinical manifestations of AD were compared for effectiveness in the 
management of symptoms. The findings suggest Ginkgo Biloba is the most effective and widely 
used herbal supplement in the treatment for cognitive decline in AD. Other supplements 
including Saffron, Curcumin, Cistanches Herba, and Sage were found to improve memory 
function and activities of daily living in individuals with AD. Herbal supplements can be cost 
effective and easier to retrieve for many individuals in comparison with prescriptive drug 




supplements, the limitations of these studies make the application of the results problematic. 
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Alzheimer’s disease (AD) affects over 5 million individuals in the United States 
annually. Due to the older generation population growing, by the year 2050, the number of 
individuals living with AD is projected to triple. (Latest Alzheimer’s Facts and Figures, 2016).  
Although there is no cure for AD, there are many prescriptive pharmacologic agents used to help 
manage the clinical manifestations of the disease.  Agents used to treat AD include 
cholinesterase inhibitors, antidepressants, antipsychotics, tricyclic antidepressants, and 
benzodiazepines. These pharmacologic agents lessen memory loss and confusion, and treat mood 
and sleep changes. Complementary and alternative medicines (CAM) and supplements are also 
used in the treatment of AD, however indications for their use and effectiveness during the 
progression of AD have not been examined.  
Although prescriptive pharmacologic therapy is widely used by individuals for the 
treatment and management of AD, the use of herbal supplements in relation to AD is not widely 
studied. Over–the-counter, herbal supplements are used daily for a variety of different ailments 
including; improving memory function, lowering cholesterol, preventing colds, preventing 
nausea and vomiting, and lessening joint pain.  Although there are herbal supplements 
recommended for patients with AD, their effectiveness in regards to symptom management and 
disease progression has not been established. Most studies conducted on the use of herbal 
supplements and their effectiveness at managing the clinical manifestation of AD have been 






Clinical manifestations of AD are often debilitating and difficult to control. Although 
pharmacological therapy is the most widely prescribed and used treatment plan for controlling 
the signs and symptoms of AD, some individuals prefer complementary and alternative therapies 
for a variety of reasons. There is a lack of evidence to support the use of herbal supplements on 
managing the clinical manifestations of AD as a solo therapy or in concurrence with prescribed 
agents. Herbal supplements must be further evaluated to better understand the risks and benefits 
















The purpose of this literature review is to examine the use and effectiveness of herbal 
supplements and their benefits on minimizing clinical manifestations of AD. There is insufficient 
research to show herbal supplements have a positive and significant effect on the clinical 
manifestations of AD. There is also a lack of evidence on when herbal supplements should be 
included as part of an individual’s therapy and how early herbal supplements should be started in 
treating the manifestations of the disease as it progresses in symptom severity. Most of the 
research has been based on small sample sizes and inconsistently designed research methods, 
yielding mixed or insignificant results.  
Understanding the benefits of herbal supplement use for controlling the clinical 
manifestations of AD can provide options for an individual’s course of treatment, either as solo 
therapy or as an adjuvant to prescriptive therapy. Research is needed to educate individuals with 
AD about different herbal and drug therapy options they can use to help control certain clinical 
manifestations of the condition, including memory loss and sleep disturbances. Individuals may 
prefer CAM treatments over pharmacologic treatments, so healthcare providers must obtain the 
knowledge on herbal supplements and their safety and effectiveness to help aid individuals in the 






A literature review was performed using research articles available from 1995 to 2016 
regarding the use of herbal supplements and their relationship in managing clinical 
manifestations of Alzheimer’s disease. The focus was mainly related to the use of herbal 
supplements as drug therapy for Alzheimer’s disease. Databases that were used to search for 
articles included Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
Educational Resources Information Center (ERIC), Elton B. Stephens Co. Host (Ebsco Host), 
Medical Literature On-line (Medline), and Psychological Information Database (PsychINFO). 
Searches used a combination of the following terms: Alzheimer’s, dementia*, herbal 
supplement*, clinical manifestation*, symptom*, benefit*, and risk*. Inclusion criteria consisted 
of 1) published research in English, 2) herbal supplements used at all stages of AD and as 
adjuvant therapy to prescriptive agents, and 3) herbal supplements used in AD to control clinical 
manifestation of the condition.  Articles that were excluded focused on AD therapy with only 
prescriptive agents and AD treatments that did not include the use of herbal supplements. 
Each article was evaluated and individually critiqued for relevance to the topic and 
application to the use of herbal supplements in people with dementia.  In the appendices, Table 1 
summarizes the findings for each article that was reviewed for this thesis. Studies in this review 
include both quantitative and qualitative studies, and systematic literature reviews that were 
published between 1998-2016.  None of the single articles included in this research were 
included in the systemic literature reviews. The studies were published in a range of different 




Arab Emirates. The data was extracted to synthesize the relationship between the benefits of 
herbal supplements in controlling the clinical manifestations of AD. Subsequently, all the 
critiqued articles were synthesized by the researcher, and key findings were extracted along with 
consistent and inconsistent findings and gaps in the literature. Limitations of the study and 


















 AD, the leading cause of dementia, is a progressive, neurological disorder that destroys 
brain cells, causing memory loss and dysfunction. The underlying pathophysiologic cause of AD 
is not completely understood, however, research has highlighted the clinical manifestations and 
expected progression of the disease. AD is thought to be caused by the buildup and degradation 
of amyloid beta peptides in the brain. An increase of amyloid beta peptides causes neurologic 
inflammation in the central nervous system, both in the blood brain barrier and the brain 
parenchyma, resulting in neurofibrillary tangles and neuron remodeling. In addition, peripheral 
immune cells also have the ability to assist in the neuro-inflammatory process in the blood brain 
barrier and brain parenchyma. Research in brain injury related to AD suggest the neuro-
inflammatory response may lead to neurodegeneration, causing brain damage (Dá Mesquita et 
al., 2016). 
 There is an abundance of known risk factors leading to AD. Genetics and environmental 
factors can influence a diagnosis of AD in individuals that exhibit the symptoms. A leading risk 
factor for AD is the expression of the ApoE ε4 allele. This allele is found in the majority of 
persons with AD, and has a direct connection to the development of AD and the course of the 
disease process. ApoE ε4 may also increase the severity of vascular risk factors associated with 
AD. Other risk factors include high cholesterol, smoking, cognitive impairment issues, low 
education levels, female gender, elevated homocysteine levels, and elevated human placental 
lactogen (Panpalli Ates, Karaman, Guntekin, & Ergun, 2016). These risk factors should be 




individuals with risk factors may be tested for the ApoE ε4 allele to help make the diagnosis. 
With continuous research on the ApoE ε4 allele, researchers may be able to find better therapies 
for the management of AD and for therapy that can lead to improved quality of life in individuals 
suffering from the clinical manifestations of AD. In addition, further research on benefits of 
herbal supplements that may affect the ApoE ε4 allele is needed to determine when this therapy 
should be started in the course of AD.    
 AD progresses through four stages: predementia, moderate, mild, and severe. 
Predementia levels can be measured by arterial spin-labelling cerebral blood flow (ASL-CBF). 
Stage 1 predementia is defined as a decrease in ASL-CBF, with abnormal amyloid-β (Aβ) in 
both the temporal and parietal regions in the brain. Stage 2 predementia has both abnormal Aβ 
and total-tau with decreased ASL-CBF in the temporal regions of the brain (Binnewijzend et al., 
2016).  As the CBF decreases, AD advances into more severe stages. After the predementia 
stages, an individual will progress through multiple phases of AD. In the mild stage of AD, 
individuals begin to have trouble remembering recent events, misplace items, and have a tough 
time planning events. These individuals are still able to function independently, but start to 
withdraw themselves from certain events and daily tasks. The moderate or middle stage of AD 
begins when an individual can’t recall what day it is, or mistake people in their family for the 
wrong person. The confusion and forgetfulness manifests and progressively worsens. The 
individual will need assistance with certain activities of daily living. In the final stage, the severe 
or late stage of AD the individual requires total care. The individual is unable to converse, and 
physical abilities, including walking become a challenge. The disability will progress and result 




in AD is usually infection or respiratory failure (Alzheimer’s stages, 2015). Medications or 
alternative therapies can be used at any stage in an effort to control symptoms or delay 
progression, but they are not curative.  
 The predominant clinical manifestations of AD are progressive memory loss and changes 
in mental status. These often manifest as apathy, delusions, hallucinations, anxiety, agitation, and 
irritability (Tokuchi et al., 2016). Some individuals will become extremely violent, while others 
prefer isolation. Due to the progressive memory loss associated with AD, recognition of people, 
places, and objects becomes increasingly difficult to distinguish.  For example, individuals with 
later stages of AD often fail to recognize family members, or accuse loved ones of stealing. 
Often times, an individual with AD has realistic delusions that their significant other is having an 
affair, which leads to anger, mistrust, and frustration. AD is difficult to manage because of the 
differentiating manifestations of each individual. Likewise, individual’s that are taking 
prescription drug therapy or herbal supplements will often present with varying response to these 
agents and the majority will show some form of AD clinical manifestations despite therapy. 
 Pharmacological therapies are most often used to manage the clinical manifestations of 
AD. Some of the most common drugs used for AD are Acetylcholinesterase Inhibitors (AChEI), 
N-Methyl-D-asparate Receptor Antagonists (NMDA), and Amyloid Binders. AChEI’s are used 
to increase the brain’s cholinergic functions, and are usually well tolerated. NMDA’s work to 
block the overstimulation of nitric oxide. Overstimulation of nitric oxide leads to cell death, so 
NMDA’s are a common treatment individuals receive. Amyloid Binders help to prevent the 
formation of Aβ senile plaques.   (Mendiola-Precoma, Berumen, Padilla, & Garcia-Alcocer, 




well as a variety of other medications to manage manifestations, including mood changes, and 
sleep disturbances. 
  Nonpharmacological therapies, or CAM, are not as widely used to treat the clinical 
manifestations of AD. However, CAM such as exercise, mental challenges, folic acid 
supplements, and the Mediterranean diet have been shown to improve cognitive function in 
individuals with AD (Mendiola-Precoma et al., 2016). Herbal supplements are not commonly 
known for the management of AD, however certain herbal supplements may have the ability to 
help prevent the start of AD, or help to manage the cognitive decline of the brain once the 
disease is already diagnosed. Herbal supplements are used by many people with AD, but only 
limited studies have found any statistical evidence to support their use.  
The use of herbal supplements in AD and their effectiveness in controlling the clinical 
manifestations of the condition is not fully understood. Although research suggests herbal 
supplements can have a positive impact on the clinical manifestations of AD, much of the 
research was based on small sample sizes and may not be applicable to the larger population.  
There is no significant evidence to support the therapeutic benefits of herbal supplements for the 
treatment of clinical manifestations of AD, such as memory loss and irritability.  Although 
current research provides us with mostly inconclusive results, several studies showed promising 
results with certain herbal supplements, supporting the need for further research on the topic.  
Herbal supplements are regulated differently than prescription pharmacologic agents, 
causing many individuals to misunderstand the safety and use of herbal-based products. Herbal 
supplements are often misused by individuals because they choose to self-treat instead of 




agree they are an effective and a safe means of treatment (Gray & Rutledge, 2013). Individuals 
often appreciate that herbal supplements cost less than prescriptive drug therapies, and many 
would prefer herbal supplements if health insurance covered the costs (Gray & Rutledge, 2013). 
Individuals with AD often use herbal supplements as part of their treatment and begin 
taking herbal supplements in the early stages of the disease. By beginning the herbal supplement 
use in the early stages of AD, individuals hope to preserve their memory function and delay 
other clinical manifestations of the disease as much as possible. In most cases, individuals that 
have AD are willing to try herbal supplements in conjunction with prescriptive agents to help 
control the manifestations of the disease. 
 Herbal supplements commonly used to treat AD include flavonoids, resveratrol, and 
gingko biloba. After several small clinical trials, Flavonoids have been considered effective in 
the treatment of AD and aid in protecting neurologic functions (Mendiola-Precoma et al., 2016). 
Resveratrol has been shown to assist in protecting neurons from cell death and oxidation. It is an 
anti-inflammatory substance, and has also been shown to promote the normal function of neural 
mitochondria (Mendiola-Precoma et al., 2016).  Ginkgo biloba is the most researched herbal 
supplement in relation to AD. Ginkgo biloba used in combination with cholinesterase inhibitors 
show a significant improvement on a mini mental state examination (MMSE) in individuals with 
AD, however both gingko biloba and the cholinesterase inhibitor used alone did not show a 
substantial improvement on MMSE scores (Canevelli et al., 2014). Gingko biloba is known to 
have minimal side effects, and other herbs such as sage and balm have been found to have 
memory improving effects as well (Perry, Pickering, Wang, Houghton, & Perry, 1998). There 




but the lack of substantial research and knowledge related to their effectiveness and ability to 
improve the quality of life in individuals with AD makes their use questionable.  
Nonetheless, studies have suggested fewer sleep disturbances and improved memory 
function when individuals with AD include certain herbal supplements in their treatment. One 
study showed the therapeutic effect of Ginkgo Biloba had similar effects as Donepezil, which is 
a pharmacologic drug that treats impairment of memory. Individuals preferred the use of Ginkgo 
Biloba compared to Donepezil because it had minimal side effects compared to Donepezil (Perry 















 Fourteen studies related to herbal supplement effectiveness on the clinical manifestations 
of AD were included in this literature review. Of the fourteen studies reviewed, five studies 
solely focused on the effectiveness of herbal supplements compared to a placebo group. These 
studies indicated that herbal supplements can show an improvement in individual’s cognitive 
function through better scores on the short cognitive performance test (SKT), the 
Neuropsychiatric inventory (NPI), Alzheimer’s Disease assessment scale-cog (ADAS-Cog), and 
the Clinical-Dementia Rating scale (CDR). These citations also concluded no harm was found by 
using an herbal supplement as treatment.  One citation compared a sole pharmacologic treatment, 
which is most often used in managing the clinical manifestations of AD, to an herbal supplement 
combined with a pharmacologic treatment. This study found the group receiving the combination 
treatment had a much higher Mini-mental status exam (MMSE) score compared to the solo 
pharmacologic therapy. Another citation compared solo pharmacologic treatment with solo 
herbal supplement treatment and both displayed similar benefits. The remaining seven citations 
were based on qualitative studies and literature reviews. These studies suggested decreased 
production of Aβ plaques, improvement in behavioral and cognitive decline, neuroprotective 
effects, anti-oxidant effects, and improving both quality of life and activities of daily living.  
Table 1 discusses the findings of the articles, which were analyzed to determine the 
benefits of herbal supplements in treating the clinical manifestations of AD. The researched 
examined within this thesis provides a framework of herbal supplement use in managing the 




Resveratrol, and Curcumin were the most widely researched. Ginkgo Biloba had the most 
significant and reliable results for controlling the clinical manifestations of AD.  
Ginkgo Biloba  
 Ginkgo Biloba is the most widely studied herb in relation to treating manifestations of 
AD, however, mixed results regarding the effectiveness have been found. Spatial memory, one 
of the deficits frequently affected in early AD, includes recognizing your hometown or the layout 
of a house. Gingko biloba was found to have protective effects against spatial cognitive 
impairment in early AD (Anekonda & Reddy, 2005). In another study Ginkgo Biloba was 
combined with AChEI’s and was compared to solo AChEI treatment. Although the sample size 
was 828, only 29 participants received the combined treatment. The combined treatment showed 
a significantly higher mini-mental status examination (MMSE) score than solo drug therapy with 
an AChEI, however it did not show a significant improvement in the ADAS-Cog score or 
activities of daily living (ADL’s) (Canevelli et al., 2014). Furthermore, a Ginkgo Biloba 
supplement of EGb 761 was studied in a trial against a placebo treatment group. The Egb 761 
group showed an SKT score improvement of -1.4 and a total NPI increase of -3.2, while the 
placebo group showed minimal change (Ihl et al., 2011). In two qualitative studies both showed 
Ginkgo biloba to improve cognitive function in patients with AD (Mendiola-Precoma et al., 
2016) (Perry et al., 1998). A literature review examined 6 articles on Ginkgo Biloba and 5 of 
these articles showed Ginkgo Biloba having a positive impact on improved cognitive functions 
and activities of daily living in individuals with AD (Yang et al., 2014). Although the majority of 
the studies have shown beneficial effects with the use of Ginkgo Biloba, further research is 




studies examining the use of Gingko biloba were limited to early onset of AD manifestations, 
such as forgetfulness and spatial recognition, and did not address issues related to advanced 
disease or progression of symptoms. 
Curcumin 
 Aβ plaque accumulation noted on advanced scanning techniques, such as magnetic 
resonance imaging (MRI) of the brain, is one of the main signs of AD. In a research study 
involving the effects of curcumin intake in people with AD, curcumin blocked the aggregation of 
Aβ1–40 and the formation of Aβ1–42 fibrils and oligomers. These substances accumulate in the 
brain as individual’s age and are associated with the onset of AD. In the same research, the 
accumulation of Aβ plaques was found to be reduced in aging mice (Anekonda & Reddy, 2005). 
A study evaluating the effects of curcumin on mice found that the mice receiving curcumin were 
able to perform better in memory task related activities, and showed improvement in 
spontaneous behavior, compared to mice in the control group not receiving curcumin (Mi Hye, 
Sung-Hoon, & Woong Mo, 2014).  Further research in human participants could possibly 
provide insight into the beneficial effects of curcumin in slowing the progression of plaque 
formation in the brain. 
Saffron 
 Saffron was shown to be safe and effective in treating certain clinical manifestations of 
mild-moderate AD including fatigue, depression, and memory loss. Saffron used as the sole 
treatment for AD showed significant improvement on the ADAS-Cog and CDR tests compared 




level of cognitive dysfunction is present in the individual. By week 16 of the trial, the group 
receiving saffron improved by -3·69 on the ADAS-Cog and -0·67 on the CDR test. No 
significant difference was found in adverse effects including dizziness, dry mouth, and nausea 
between the saffron and placebo groups. These results concluded that although saffron was found 
effective, it was only for short term use and needs to be further evaluated. (Akhondzadeh et al., 
2010) 
Resveratrol  
 Resveratrol has been studied for use in a variety of conditions, including AD. Resveratrol 
has been tested in both humans and rats and was found to have multiple benefits. In rats, 
resveratrol prevented oxidative stress and both intracerbroventrical and straptozotocin induced 
cognitive impairments. Oxidative stress is an imbalance between reactive oxygen species (ROS) 
and the body’s ability to detoxify and repair the resulting damage (Anekonda & Reddy, 2005). 
Oxidative stress arises early on in the process of AD, preceding the events of plaque and 
neurofibrillary tangles. In human cells, resveratrol protected from ROS which keeps the body’s 
normal balance preventing oxidative stress, and also prohibited DNA fragmentation  (Anekonda 
& Reddy, 2005). It also showed an increased life span in relation to resveratrol, however this 
trial was performed on mice (Giulietti et al., 2016). Lastly, in a qualitative study resveratrol as a 
supplement showed neuroprotective effects in AD. Resveratrol activates SIRT1 which is a sirtuin 
that protects neurons from apoptotic process (cell death) and oxidative stress. SIRT1 also 
displayed reduction of the pathway of glial cells that are unprotected from Aβ. These 
neuroprotective effects help promote cell survival and the correct functioning of mitochondria.  





 One study that was reviewed in this literature dealt with omega-3 fatty acids and its effect 
on cerebrospinal fluid in individuals with AD. This study had a small sample size (n=33) and 
showed minimal cognitive benefits on individuals with mild AD. The trial on individuals with 
moderate-severe AD was unsuccessful and showed no benefit (Freund Levi et al., 2014). 
Cistanches Herba 
 Cistanches Herba is a desert plant that is said to have a positive impact on memory 
function. The effects of Cistanches Herba on the clinical manifestation of AD were compared to 
Donepezil (Aricept®) an AChEI commonly prescribed for AD, and no treatment for individuals 
with mild-moderate AD. Cistanches Herba and Donepezil both showed close to the same 
improvement in cognitive function and slowing down hippocampus atrophy. Hippocampus 
atrophy is a common sign of AD and with MRI can be tracked in moderate-severe stages of AD. 
At week 0, all three groups had a score of about 20 on the MMSE. The higher the score on the 
MMSE, the better cognitive function the individual is displaying. By the 48th week of the study, 
the herbal and pharmacologic group improved to a score of 24 while the group receiving no 
treatment dropped to an 18. Moreover, the ADAS-cog scores showed less significant scores, but 
still displayed improvement in the two treatment groups and a degradation of score for the group 
receiving no treatment. It was also noted that Cistanches Herba is much cheaper and easier to 







 Flavonoids were discussed in a few studies and were found to be safe, portray 
neuroprotective effects, improve memory, and inhibit the production of acetylcholinesterase 
(Mendiola-Precoma et al., 2016). In one study green tea extract was discovered to reverse 
memory deficits by inhibiting AChEI activity (Anekonda & Reddy, 2005). Fig, which is under 
the class of a polyphenol, demonstrated improvements in behavioral and cognitive function in 
AD, and reduced the accumulation of Aβ (Giulietti et al., 2016). Lastly, crocus, sage, lemon 
balm, and Fuzhisan were compared to either a placebo or orthodox medication and showed an 
improvement in individuals with AD on the ADAS-Cog test (Yang et al., 2014). Herbs have 
been used for a variety of reasons for centuries, but further studies can assist in proving their 













 The studies examined for this thesis can offer insight into a complementary and 
alternative treatment for individuals with AD. Research findings showed the benefits of using 
herbal supplements as part of treatment for managing the clinical manifestations of AD. 
Although the literature review presented mixed results, the majority of studies revealed several 
positive effects that herbal supplements demonstrated in minimizing early, debilitating clinical 
manifestations of AD.  
 Using herbal supplements as part of treatment for AD may be beneficial and cost 
effective to many individuals, since herbal agents often do not cost as much as prescriptive drug 
therapy. In addition, when compared to pharmacologic agents, Ginkgo Biloba was found to have 
minimal side effects compared to Donepezil which has various side effects including dizziness, 
nausea, vomiting, and diarrhea (Perry et al., 1998). Some individuals prefer natural and herbal 
therapies compared to pharmacologic treatments, so providing information about herbal 
supplements that have been effective in reducing clinical manifestations of AD is useful. With 
millions of individuals being diagnosed with AD each year, and the number of individuals 
continuing to rise, exploring treatment options is essential. Because AD is an incurable disorder, 
pharmacologic treatment is aimed at slowing down the progression of the disease and lessening 
the symptoms. Likewise, there are many nonpharmacological treatments that can also be used to 
slow the progression of AD and its clinical manifestations, which include herbal supplements, 




(Mendiola-Precoma et al., 2016). Producing further research on nonpharmacological therapies 
can help lessen the symptoms of AD.  
 The studies portrayed a variety of different herbal supplements with many different 
benefits. Most of the herbal supplements showed benefits in improving cognitive function and 
neuroprotective effects in individuals with mild-severe AD that was in the early stages of the 
disease. Several studies compared solo pharmacological treatment with pharmacological and 
nonpharmacological treatments combined, yielding mixed results. One study showed a 
significant benefit in the individuals who took both the AChEI and Gingko Biloba (Canevelli et 
al., 2014), although the synergistic effect of the agents combined was vague and not fully 
explained.  Although many of the articles portrayed the same type of benefits with herbal 
supplements, many had small sample sizes or were tested on animals, which limits the 
applicability of the research, warranting the need for further studies.    
 Despite the limitations of small sample sizes and animal testing, the current study 
provides information on a variety of herbal supplements that have been shown to have some sort 
of positive effect on individuals with AD. It shows that herbal supplements have the ability to 
successfully treat certain clinical manifestations of this disease process. Additional research on 
herbal supplements effectiveness in managing clinical manifestations of AD would be beneficial 
to help better validate their uses.  
 In further studies, the stage of AD and the comparison to pharmacological should be put 
into more consideration. In many of the studies, the herbal supplements were compared to a 




how effective they were in comparison to pharmacological treatment. Comparing herbal 
supplement treatment findings to pharmacological treatment findings can demonstrate the 
effectiveness of herbal supplements. Comparing the herbal supplements and pharmacologic 
treatments can also provide the price differences, dosage sizes, and availability of the agents, 
which can be extremely beneficial to individuals with AD.  Several of the studies specified the 
stage of AD, whereas some of the studies did not. Each stage of AD may respond differently to 
herbal supplements, so knowing the stage may be helpful in portraying more accurate and 
reliable results. Curcumin blocked the formation of AB plaque in the brain, therefore this herbal 
supplement may be beneficial in predementia stages and may be used as a preventative measure 
for AD in the future (Anekonda & Reddy, 2005). Finally, combining herbal supplements with 
pharmacological treatment may be superior to either treatment alone (Canevelli et al., 2014). 
Studies on combining the two treatments may assist in finding the best treatment for AD overall.  
 When analyzing the studies reviewed, despite limitations, there was a consistency in 
findings with certain herbal supplements researched in a multitude of the studies. The herbal 
supplements can slow cognitive decline, produce neuroprotective effects, improve ADL’s, and 
improve memory function. Studies should be conducted on comparing herbal supplement 
effectiveness with pharmacological effectiveness to establish a better understanding of how 
beneficial herbal supplements are.  
 Complementary and alternative therapies are growing in use and can be used in a variety 
of disease processes. In specific, herbal supplements provide benefits including anti-psychotic, 
anti-inflammatory, anti-depressant, and anti-oxidant properties (Anekonda & Reddy, 2005). 




management of AD, the herbal supplement was found to be less expensive, and easier to come 
by (Li et al., 2015).   Some individuals are holistic and would prefer to use CAM instead of 
pharmacologic therapy, so having it as an option is essential.  
 In conclusion, there should be further studies on herbal supplement use in controlling 
clinical manifestations of AD.  Further studies can help to clarify the benefits of herbal 
supplements in comparison to pharmacological treatments. However, with the evidence 
presented herbal supplements can be safe and effective in treating clinical manifestations of AD 
and therefore, should be offered as a treatment option to individuals with AD. In addition, 
although a few herbal supplements showed no effect, none of the herbal supplements had a 
negative effect on managing the clinical manifestations of AD, suggesting that individuals 













 This literature review contained several limitations. The initial search examined many 
different treatments for AD, and therefore did not solely focus on the purpose of this study. Once 
a more narrow search was executed, and keywords Alzheimer’s, herbal supplement*, and 
benefit* were used, more relevant research was discovered. After excluding AD therapy focused 
only with prescriptive agents or others not including herbals, minimal studies were found. These 
findings indicate the need for further research in comparing herbal supplement benefits with 
pharmacologic treatments on treating the clinical manifestations of AD.  
 Several of the studies had small sample sizes, were tested on animals, were compared to a 
placebo rather than a pharmacological agent, and did not specify what stage of AD the 
individuals were in. Animal testing trials have discovered benefits from herbal supplements, but 
because mice and rats do not have the same brain capacity and function as a human, human trials 
with well-designed clinical trials are needed to determine human benefits. The majority of the 
studies focused on elder individuals who had mild-severe AD and used herbal supplements as the 
sole treatment for the clinical manifestations of AD. However, for some of the studies it was only 
listed that individuals had mild-severe AD. Because every stage of AD is different, it’s important 
to know the specific stage the individual is in, so that the research is more reliable. Knowing 
what stage of AD and how efficient the herbal supplements worked in that stage will give 
individuals a better understanding of when they can use the herbal supplements as a treatment.  
 The sample sizes ranged from n=26 to n=828. The smallest sample size group was one 




This study found that Cistanches Herba (herbal supplement) and Donepezil (pharmacologic 
agent) showed close to the same improvement in cognitive abilities (Li et al., 2015). This study 
provided a significant finding, so it is imperative that future studies involving larger sample sizes 
occur. The study with an adequate sample size of n=828 compared alone AChEI treatment to an 
AChEI combined with gingko biloba. The combined treatment did show a higher MMSE scored 
compared to the alone treatment, however only 29 participants chose to use the combined 
treatment, indicating the need of further clarification to understand the effectiveness of 
combining therapies (Canevelli et al., 2014). Furthermore, the other studies researched all 
showed a positive impact of herbal supplements on controlling the clinical manifestations of AD 
aside from one, but due to the small sample sizes further research is required.  
 Three of the studies in this research were performed on mice or rats. Although cognitive 
decline was found to be decreased and many of the herbals studied were found to have 
neuroprotective effects and reduce Aβ-induced oxidative stress, the studies were not performed 
on a human, making the results inconclusive. Further clinical trials need to be performed on 
humans to better understand the benefits of these herbal supplements.  
 Lastly, many of the clinical trials of herbal supplements were compared to a placebo 
group rather than a pharmacological agent. This gives the opportunity to understand the 
effectiveness of herbal supplements in managing the clinical manifestations of AD, but without 
comparing it to a pharmacological agent, understanding if herbals are as effective as these agents 
is difficult. Providing further research in comparing and/or combining the two therapies can be 




Implications for Nursing 
 Due to the slow, progressive symptomology of AD, exploring herbal treatment options 
for controlling the clinical manifestations of the disease is significant. Herbal supplements can 
slow cognitive decline and portray neuroprotective effects, so knowing that AD continuously 
gets worse over time, individuals may want to know about this treatment option. Continuing 
research on this topic is imperative, so that individuals can receive the most beneficial treatment 
for controlling the clinical manifestations of AD.  
 Individuals with AD and their caregivers should be educated on the various herbal 
supplements available as treatment options for the clinical manifestations of AD. Some 
individuals prefer complementary and alternative therapies as opposed to pharmacological 
treatments, so offering these supplements is essential. Health care facilities should implement 
herbal supplements as a complementary or alternative therapy for managing the clinical 
manifestations of AD, as there is no research that shows harm from these supplements. 
Educating health care providers on this option is important to create adequate patient satisfaction.  
 Due to numerous limitations throughout the study, further research is needed to 
determine how effective herbal supplements are in managing the clinical manifestations of AD. 
However with the research presented, herbal supplements can have a positive impact on 
managing the clinical manifestations of AD, and combining herbal supplements and 
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Age 55 and older, 
and a baseline 
MMSE score of 15-
26. 
Saffron produced a 
significantly higher 
outcome for the 
cognitive function 
on the ADAS-cog 
and CDR tests and 




cog: F = 4·12, 
d.f. = 1, P = 0·04 
 
CDR: F = 4·12, 
d.f. = 1, P = 0·04 
 
No difference in the 
adverse effects was 
observed between 
the two groups.   
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In this trial, 30 
mg/day saffron was 
being used on its 




This study showed 
that saffron is safe 
and effective in 
short term use, but 
needs further trials 
to validate this 
remedy.  















medicines as a form 
of treatment for AD 
This review was 
based off of a 






It reviews the 
current strategies for 
treating the clinical 
manifestations of 
AD with herbal 
medicines.  
Curcumin was found 
to reduce the 
accumulation of 
Aβ plaques in the 
brain.  
 
Ginkgo biloba was 











ascorbyl, vitamin E, 
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reviewed in this 
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significant benefits 




Aβ plaques, less 
cognitive decline, 
anti-oxidant effects, 
and a longer life 
span; however these 
studies were 
performed on mice 
and rats.  
 
Herbal drugs have 
been found to easily 
cross the blood 













combined with an 
AChEI was found to 
increase the 
concentration of the 
acetylcholine. 
 
Green tea extract 
worked to reverse 





are less toxic with 
less adverse effects 
than 
pharmacological 
treatments, but need 
to be further studied 
on humans to 
determine the 
greatest benefits and 
risks.  
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Involved 29 centers 
from 12 European 
countries all a part 








ranging from 10-26, 
living in a 
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significantly higher 
score on the MMSE 








AChEIs only  
-1.44±0.12 
 




score also showed 
an increase for the 
combined treatment 
group, however it 
was not statistically 
significant 
 
No differences in 
ADL’s were 
observed   
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treatment. It was 
compared to a group 
only taking 
AChEI’s for the 
treatment of the 
clinical 
manifestations of 
mild-moderate AD.  
 
 
The group receiving 
combined treatment 
showed and 
confirmed a much 
higher MMSE 
score, however 
because there was 
not a significant 
difference in the 
ADAS-Cog score 
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Ethical committee at 
Karolinska 
University Hospital 







between 15-30, and 
treatment with a 
stable dose of 
AChEI for at least 3 
months before the 
study. 
n-3 FA supplement 
group displayed 
significant increase 
in CSF EPA, DHA, 
and n-3 FA levels, 
whereas no increase 
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received a dietary 
supplement of n-3 
FA to improve the 
cognitive decline 
caused by mild-
moderate AD.  
 
Results show there 
may be some form 
of preservation of 
memory in 
individuals with 
extremely mild AD, 
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unsuccessful. 
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Systemic review of 
the most recent 
literature (129 
articles) on the 
effects of nutrition 
on progression of 
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Vitamin E showed a 
neuroprotective role 
in mice, but there 
was little evidence 
of this role in 
humans.  
 
Fig a polyphenol 
was shown to reduce 
Aβ and improve 
behavioral and 
cognitive defects in 
AD.  
Resveratrol was 
tested in mice and 
not only helped to 
control the cognitive 
decline of AD, but 
these mice also had 





Although the mice 
trials showed 
beneficial effects on 
some of the clinical 
manifestations of 
AD from these 
herbal supplements, 
not all have been 
tested on humans.  
 
More clinical trials 
are needed to define 
the benefits of these 




Ginkgo biloba was 
found to be 
ineffective in 
preventing AD, but 
was found to have 
an anti-amyloid 
aggregation effect.  
Ihl et al. 
(2011) 
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a day formulation of 
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EGb 761 treatment  
SKT score improved 
by -1.4 
NPI total score 
improved by -3.2  
 
The placebo group 
showed minimal or 




deteriorated by +0.3 
NPI total score did 
not change  
 
There was consistent 
and statistically 
significant outcome 
measures for the 




This trial included 
patients with AD, 
vascular dementia 
or a mixed form of 
dementia. 
Participants were 
given either 240 mg 
of EGb 761, or 
placebo both once a 
day for 24 weeks.  
 
Primary outcome 
measures were the 
SKT score and the 
12 item NPI score. 
 
Secondary outcome  
measures included 
the NPI caregiver 
stress score, the 
ADCS-CGIC score, 
the ADL-IS score, 
the DEMQOL-
Proxy scale, and the 
Verbal Fluency test. 
 
Participants 





the placebo group 
showed minimal to 
no change in the 
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26 participants were 
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cognitive abilities in 
AD and slow down 
hippocampus 
atrophy, suppress T-
tau, TNF-a, and 





In this trial there 
were 3 different 
groups being 
compared. 
Participants had AD 




donepezil, which is 
an AChEI, or no 
treatment at all. 
 
At 24 weeks there 
was no significant 
difference between 
the 3 groups 
cognitive abilities, 
however by the 48th 
week there were 
changes.  
 
Both the Cistanches 
Herbal group and 




showed about the 
same improvement 
as each other.  
Cistanches Herbal 
was shown to be 
much cheaper and 
easier to retrieve 
than donepezil, so 
because they 
showed about the 
same outcomes, 
some individuals 
may prefer this herb 
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research and other 
research articles.  
 
Studies throughout 
the article were 
based on 
observation of either 
human or mice.   
Pharmacological 
treatment: AChEI’s 
were shown to 
improve memory 
loss and are well 
tolerated. NMDA’s 





This study suggests 
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pharmacological 












receptors along with 
histamine receptors 
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treatment of clinical 
manifestations of 















Resveratrol is a 
polyphenol and was 
found to have 
neuroprotective 
effects on AD.  
Flavonoids are 
considered safe and 
have also been 
found to have 
neuroprotective 
effects on AD.  
Ginkgo biloba is 
shown to help 
memory function in 
AD.  
including herbal 
supplements such as 
ginkgo biloba, 
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This research article 
was designed to 
investigate the 
effectiveness of 
certain herbs on 
cognitive 
impairment in AD.  
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research articles.  
 
Studies throughout 
the article were 
based on 
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Berberine is an herb 







shown to improve 
spontaneous 






The majority of 
these herbs benefits 
were shown through 
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rats, making it an 
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conclusion for the 
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Puerarin was shown 
to decrease Aβ-
induced cell death.  
 
Silibinin is thought 
to improve 
recognition memory 
and protect against 
Aβ-induced 
oxidative stress.  






This study examines 
different methods 
and herbal 
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research and other 
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Ginkgo biloba was 
proven to improve 
cognitive function in 
mild-moderate AD.  
 
Balm essential oil 
combined with 
lavender showed a 
slight increase in 
general functioning 
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A Chinese medicine 
known as Salvia was 
reported to be 
effective in memory 
function in 40% of 
patients with AD.  
 
Ancient Greeks used 
rosemary to 






from around the 
world. Although 
some of these 
treatments weren’t 
on patients with 
AD, these herbs 
were still shown to 
improve memory 
which is one of the 
main clinical 
manifestations of 
AD. These herbs 
have been around 
for ages, and should 
be further 
researched to clarify 
exactly what they 
are capable of.  
Posadzki et al. 
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Massachusetts 
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6 articles on 4 data 
bases from their 
Only 6 articles met 
the inclusion 
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these articles, the 
evidence to support 
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of selection bias, 
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validity assessment 
tool, robustness of 
data analysis and 
supportiveness of 
conclusions. 
CAM for the 
treatment of AD is 
unclear.  
 
As some herbal 
medicines show a 
promise in 
managing AD, 




balm, sage, ginkgo 
biloba, lycopodium 
serratum, and panaz 
ginseng.  
 
Out of these herbal 
supplements ginkgo 
biloba and ginseng 
were shown to 
improve cognitive 
function and quality 
of life, however 
were only compared 
to placebo and not 
current drug therapy 
for AD.  
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This study included 
one group of mice 
receiving their 
normal feeding and 
another group of 
mice receiving 
added dietary 
supplements in their 
food.  
 







could be considered 
as a strategy to slow 
cognitive decline in 
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This study was done 
in mice therefore, 
more research needs 
to be done to prove 
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have better 
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Crocus, sage, lemon 
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improve cognitive 
function through the 
ADAS-Cog test. 
These were all 
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were not compared 
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positive effect on 
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risk of bias 
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extracted 
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meta-analysis and 
none were able to 




Bias and low quality 
trials prove the need 
for further studies to 
define the role of 




compared the oral 
administration of 








CHMK is not able 
to be determined by 
this study because 



















































Key Search Terms: Alzheimer’s, dementia*, herbal supplement*, clinical manifestation*, symptom*, 
benefit*, and risk* 
Limiters: English language, peer reviewed, published 1995-2016 
       Potential relevant citations identified after screening data bases. 
   (CINAHL, ERIC, Ebsco Host, Medline, and PsychINFO)  
  n=72 
            Excluded through 
inclusion 
materials not 
being met.  
         n=49 
          Studies and Articles retrieved for further review  
         n=35 
          Studies and articles 
excluded following in 
depth analysis; 
concluding they did 
not meet criteria. 
       n=27 
            Studies and articles that encumbered 
inclusion criteria  
            n=23 
              Additional studies and articles were reviewed and hand 







Alzheimer's stages: How the disease progresses - Mayo Clinic. (2015, November 24). Retrieved 
October 23, 2016, from http://www.mayoclinic.org/diseases-conditions/alzheimers-
disease/in-depth/alzheimers-stages/ART-20048448 
Latest Alzheimer’s facts and figures. (2016). Retrieved September 21, 2016, from 
http://www.alz.org/facts/ 
Akhondzadeh, S., Shafiee-Sabet, M., Harirchian, M. H., Togha, M., Cheraghmakani, H., 
Razeghi, S., . . . Moradi, A. (2010). Saffron in the treatment of patients with mild to 
moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial. 
Journal of Clinical Pharmacy & Therapeutics, 35(5), 581-588. doi:10.1111/j.1365-
2710.2009.01133.x 
Anekonda, T. S., & Reddy, P. H. (2005). Can herbs provide a new generation of drugs for 
treating Alzheimer's disease? Brain Research. Brain Research Reviews, 50(2), 361-376.  
Binnewijzend, M., Benedictus, M., Kuijer, J., Flier, W., Teunissen, C., Prins, N., . . . van 
Berckel, B. N. M. (2016). Cerebral perfusion in the predementia stages of Alzheimer's 
disease. European Radiology, 26(2), 506-514. doi:10.1007/s00330-015-3834-9 
Canevelli, M., Adali, N., Kelaiditi, E., Cantet, C., Ousset, P.-J., & Cesari, M. (2014). Effects of 
Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase 
inhibitors: Data from the ICTUS study. Phytomedicine, 21(6), 888-892. 
doi:10.1016/j.phymed.2014.01.003 
Dá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. 




amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience 
And Biobehavioral Reviews, 68, 547-562. doi:10.1016/j.neubiorev.2016.06.014 
Freund Levi, Y., Vedin, I., Cederholm, T., Basun, H., Faxén Irving, G., Eriksdotter, M., . . . 
Palmblad, J. (2014). Transfer of omega-3 fatty acids across the blood-brain barrier after 
dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation 
in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine, 
275(4), 428-436. doi:10.1111/joim.12166 
Giulietti, A., Vignini, A., Nanetti, L., Mazzanti, L., Di Primio, R., & Salvolini, E. (2016). 
Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and 
their Effect on Drug Therapy Outcome. Current Neuropharmacology, 14(2), 177-190. 
doi:10.1093/ijnp/pyu115.  
Gray, D. C., & Rutledge, C. M. (2013). Herbal supplements in primary care: patient perceptions, 
motivations, and effects on use. Holistic Nursing Practice, 27(1), 6-12. 
doi:10.1097/HNP.0b013e318276fb32 
Ihl, R., Bachinskaya, N., Korczyn, A. D., Vakhapova, V., Tribanek, M., Hoerr, R., & 
Napryeyenko, O. (2011). Efficacy and safety of a once-daily formulation of Ginkgo 
biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized 
controlled trial. International Journal of Geriatric Psychiatry, 26(11), 1186-1194. 
doi:10.1002/gps.2662 
Li, N., Wang, J., Ma, J., Gu, Z., Jiang, C., Yu, L., & Fu, X. (2015). Neuroprotective Effects of 




Based Complementary And Alternative Medicine: Ecam, 2015, 103985-103985. 
doi:10.1155/2015/103985 
Mendiola-Precoma, J., Berumen, L. C., Padilla, K., & Garcia-Alcocer, G. (2016). Therapies for 
Prevention and Treatment of Alzheimer’s Disease. BioMed Research International, 2016, 
1-17. doi:10.1155/2016/2589276 
Mi Hye, K., Sung-Hoon, K., & Woong Mo, Y. (2014). Mechanisms of Action of Phytochemicals 
from Medicinal Herbs in the Treatment of Alzheimer's Disease. Planta Medica, 80(15), 
1249-1258. doi:10.1055/s-0034-1383038 
Panpalli Ates, M., Karaman, Y., Guntekin, S., & Ergun, M. A. (2016). Analysis of genetics and 
risk factors of Alzheimer's Disease. Neuroscience, 325, 124-131. 
doi:10.1016/j.neuroscience.2016.03.051 
Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P., & Perry, N. S. L. (1998). Medicinal 
plants and Alzheimer's disease: integrating ethnobotanical and contemporary scientific 
evidence. Journal of Alternative & Complementary Medicine, 4(4), 419-428. 
doi:10.1089/acm.1998.4.419 
Tokuchi, R., Hishikawa, N., Sato, K., Hatanaka, N., Fukui, Y., Takemoto, M., . . . Abe, K. 
(2016). Differences between the behavioral and psychological symptoms of Alzheimer's 
disease and Parkinson's disease. Journal Of The Neurological Sciences, 369, 278-282. 
doi:10.1016/j.jns.2016.08.053 
Yang, M., Xu, D. D., Zhang, Y., Liu, X., Hoeven, R., & Cho, W. C. S. (2014). A Systematic 




with Meta-Analyses of Intervention Effect of Ginkgo. American Journal of Chinese 
Medicine, 42(3), 505-521. doi:10.1142/S0192415X14500335 
   
 
 
 
